, we are in an advanced stage of engineering and the delivery is scheduled in the month of November 2015.
and PP14 plants will each have a combined net electric output of 1,980 MW.
First-trimester maternal serum PP13
in the risk assessment for preeclampsia.
These included a global licensing agreement to develop assay kits for the ADAM12 biochemical marker, which has broad potential in maternal health screening for fetal chromosomal abnormalities; and the securing of global rights for PP13
(Placental Protein 13), a new prospective biomarker for identifying patients at risk for pre-eclampsia in the first trimester.
A subsidiary unit of the Japanese Yokogawa Electric, Yokogawa Saudi Arabia, has gained contracts to supply distributed control systems (DCS) for the PP13
and PP14 combined cycle power plants in Riyadh, Saudi Arabia.
NYSE: PKI), a world leader in Health Sciences and Photonics, announced that it has secured the exclusive global rights to PP13
for identifying patients at risk for preeclampsia developed by DTL.
05 units purchased in Saudi Arabiaa 12 units for PP13
and PP14 will be delivered in late 2014 and early 2015.
Saudi Electricity Company (SEC) plans to build PP13
in Riyadh, Saudi Arabia.
Further testing of PP13
will determine whether it can detect the predisposition for preeclampsia to allow for such improved patient management.
According to plans, PP13
and PP14 will have 12 units of GE 7F-5 gas turbines, 4 GE steam turbines and 16 units of generators and are an additional expansion of GE s 7F-5 gas turbine technology deployed in the PP12 project in the Kingdom.
and PP14 will contain 12 GE 7F-5 gas turbines, four GE steam turbines and 16 generators and are a further expansion of GE's 7F-5 gas turbine technology used in the PP12 project in the country.
Company: SANRAD Booth/Stand: PP13
Media Contact: Zophar Sante Phone: 510-521-2424 E-mail: zophar@sanrad.